Tag Archives: Oncology

Options for Oncologists Get Tougher

By William Looney | Published: August 4, 2010
How does the business of oncology practice fare today? The National Comprehensive Cancer Care Network (NCCN), which allies 21 of the world’s leading cancer care and research centers in developing state-of-the-art practice guidelines, decided to ask that question in a survey it conducted among several hundred oncology specialists earlier this year. The results, a sobering [...]
Posted in Strategy | Also tagged , | 2 Comments

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment

Astellas and OSI Come Together

By Oriana Schwindt | Published: May 19, 2010
The months-long saga is finally over: Astellas’ enhanced offer of $57.50 a share—around $4 billion—has finally netted it Melville, NY-based OSI Pharmaceuticals. The Japan-based pharma first extended an acquisition offer of $52 per share ($3.5 billion) to OSI on March 1, only to be met with a resounding “Nay” from the board, which said $52 [...]
Posted in Deals, News, Strategy | Also tagged , , , , , | Leave a comment

Q&A with Steven Paul: Lilly’s New Development Plan

By George Koroneos | Published: September 23, 2009
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy | Also tagged , , , , , , | 3 Comments

Lilly Puts Up $6.5 Billion for ImClone

By George Koroneos | Published: October 6, 2008
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. ImClone also [...]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment